Editor’s Note
This article was published online on Jan. 28, 2021.
CONTINUE TO SITE
OR WAIT null SECS
- About Us
- Advertise
- Editorial Information
- Contact Us
- Do Not Sell My Personal Information
- Privacy Policy
- Terms and Conditions
© 2021 MJH Life Sciences™ and BioPharm International. All rights reserved.
Demystifying Complex Clinical Trial Kit Prep
Natalie Balanvosky, Bryan Thompson
BioPharm International, BioPharm International-05-15-2021, Volume 2021 eBook, Issue 2
Pages: 28-32
Best practices can help ensure supply chain flexibility and viability for biologic drugs in clinical trials.
Developments in biologics and personalized medicines are reshaping the clinical trial landscape. According to Grandview Research, the global biologics market is anticipated to reach $398 billion by 2025, with growth supported by faster drug approval processes (1). Simultaneously, the increasing prevalence of cancer and rare diseases is providing the catalyst for investment in the development of targeted therapies. These precision medicines, which are tailor-made to meet unique patient needs, are expected to reach $85 billion over the next five years, representing a substantial 9.9% compound annual growth rate (2).
Read this article in BioPharm International’s Partnerships for Outsourcing May 2021 eBook.
About the authors
Natalie Balanvosky is just-in-time manufacturing solutions manager, and Bryan Thompson is production manager, both with Almac Clinical Services.
Article Details
BioPharm International
eBook: Partnerships for Outsourcing, May 2021
May 2021
Pages: 28–32
Citation
When referring to this article, please cite it as N. Balanvosky and B. Thompson, “Demystifying Complex Clinical Trial Kit Preparation," BioPharm International Partnerships for Outsourcing eBook (May 2021).
Related Content: